As of the Summer 2020 Release, CIBMTR implemented a hard stop when reporting multiple genetically modified cellular therapies and HCTs that require follow-up forms. This new functionality has been implemented to reduce center reporting burden and redundancies when having to report multiple cellular therapy and HCT events for a single patient.

Instead of having two sets of forms due at different timepoints, all applicable follow-up forms will be due at the same timepoints moving forward (i.e. Forms 2450 +4100 or 2100+4100). Duplicate questions on the paired forms will be disabled in identified reporting scenarios, listed below. Defined hard stops in addition to the custom enabling and disabling will streamline follow-up reporting when a patient receives infusions for multiple indications with overlapping time periods.

Identified Reporting Scenarios

  • Scenario 1: The recipient receives a transplant and subsequently receives a genetically modified cellular therapy. For more information about this scenario, review this diagram.
  • Scenario 2: The recipient receives a genetically modified cellular therapy and subsequently receives a transplant. For more information about this scenario, review this diagram.
  • Scenario 3: The recipient receives a transplant and subsequently receives a non-genetically modified cellular therapy (no change from current state, hard stop rules not applied). For more information about this scenario, review this diagram
  • Scenario 4: The recipient receives a non-genetically modified cellular therapy and subsequently receives a transplant (no change from current state, hard stop rules not applied). For more information about this scenario, review this diagram
  • Scenario 5: The recipient receives three or more infusions. For more information about this scenario, review this diagram
Last modified: Jul 15, 2020